瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

已收盘 10-21 16:08:20

52.650

+0.400

+0.77%

最高54.350	最低52.250	成交量4.81万
今开52.250	昨收52.250	日振幅4.02%
总市值89.51亿	流通市值89.51亿	总股本1.70亿
成交额256.19万	换手率0.03%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":52.65,"timestamp":1792570100010,"preClose":52.25,"halted":0,"volume":48088,"delay":0,"changeRate":0.00765550239234447,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"已收盘","change":0.4,"latestTime":"10-21 16:08:20","open":52.25,"high":54.35,"low":52.25,"amount":2561929,"amplitude":0.040191,"askPrice":52.8,"askSize":200,"bidPrice":52.65,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792632600000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":52.25,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":0.196213,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2676653250","title":"瑞博生物-B盘中涨超9% 拟收购Ribocure Pharmaceuticals AB剩余股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2676653250","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676653250?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:30","pubTimestamp":1792463400,"startTime":"0","endTime":"0","summary":"瑞博生物-B盘中涨超9%，截至发稿，股价上涨4.45%，现报52.85港元，成交额759.83万港元。目标公司Ribocure Pharmaceuticals AB为一家于2022年2月根据瑞典法律组织成立的临床阶段生物技术公司。目标公司目前拥有五个药物发现和临床前阶段项目，其中两项已经推进至接近临床申报阶段及两个主要对外授权合作项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvv6587001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676686825","title":"瑞博生物-B(06938.HK)拟收购Ribocure Pharmaceuticals AB余下49.71%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2676686825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676686825?lang=zh_cn&edition=full","pubTime":"2026-10-19 20:34","pubTimestamp":1792413273,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676688482","title":"瑞博生物-B(06938.HK)拟换股收购Ribocure剩余49.71%股权 实现全资控股siRNA研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2676688482","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676688482?lang=zh_cn&edition=full","pubTime":"2026-10-19 19:16","pubTimestamp":1792408571,"startTime":"0","endTime":"0","summary":"格隆汇10月19日丨瑞博生物-B宣布，于2026年10月16日，公司与少数股东订立换股协议，据此，在受限于及按照换股协议的条款及条件的情况下，公司已有条件同意收购，而少数股东已分别及有条件同意出售目标股份，致使公司将持有目标公司的全部权益。截至公告日期，公司持有目标公司已发行股份总数的约50.29%。交割后，目标公司将成为公司的全资子公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261019/32401392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100965529","title":"瑞博生物-B（06938）拟发行逾1408万股H股收购旗下Ribocure全部股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1100965529","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100965529?lang=zh_cn&edition=full","pubTime":"2026-10-19 19:01","pubTimestamp":1792407693,"startTime":"0","endTime":"0","summary":"2026年10月19日，瑞博生物-B公布，于2026年10月16日与少数股东签订换股协议，拟以股份互换方式收购其现持有50.29%目标公司Ribocure Pharmaceuticals AB剩余49.71%已发行股份。本次交易对价为向四名少数股东发行14,087,085股新H股，对应换股比例为1股目标公司股份换取15股瑞博生物-B H股。对价股份占公告日已发行股份总数约8.26%，占扩大后已发行股份总数约7.63%。根据估值报告，Ribocure 100%股权于2026年6月30日的评估价值为19.97亿瑞典克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673025526","title":"港股异动 | 瑞博生物-B(06938)盘中涨超5% 公司在欧盟提交RBD3133注射液I期临床申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2673025526","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673025526?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:12","pubTimestamp":1791439977,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B(06938)盘中涨超5%。截至发稿，涨3.64%，报55.55港元，成交额1470.97万港元。消息面上，瑞博生物公布，已在欧盟提交公司靶向INHBE 的siRNA产品RBD3133注射液以超重及肥胖症为治疗适应症的I期临床试验申请。该试验将提供RBD3133在人体的首次评估，并将为进一步临床开发奠定基础。RBD3133为公司在心血管及代谢疾病领域siRNA产品开发组合的关键里程碑，有望成为治疗减重相关心血管及代谢疾病的基石药物。作为公司在肥胖治疗领域的首款候选药物，RBD3133体现了公司为有重大未满足医疗需求的广大患者群开发创新药物的战略重心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FSXEmain","BK1161","BK4588","BK4585","VXUS","FESXmain","06938","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673566045","title":"瑞博生物-B(06938.HK)提交RBD3133注射液用于治疗超重及肥胖症的I期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2673566045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673566045?lang=zh_cn&edition=full","pubTime":"2026-10-08 06:41","pubTimestamp":1791412865,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149141807","title":"瑞博生物-B（06938）向欧盟递交RBD3133治疗超重及肥胖症I期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1149141807","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149141807?lang=zh_cn&edition=full","pubTime":"2026-10-08 06:40","pubTimestamp":1791412830,"startTime":"0","endTime":"0","summary":"2026年10月8日，瑞博生物-B发布自愿公告称，公司已在欧盟提交其靶向INHBE的siRNA产品RBD3133注射液用于治疗超重及肥胖症的I期临床试验申请。公告显示，RBD3133注射液通过选择性沉默编码激活素E蛋白的基因INHBE进行作用。该研究将为RBD3133在人类中的首次评估，并为后续临床开发奠定基础。瑞博生物同时提醒，RBD3133注射液最终可能无法成功开发及商业化，股东及潜在投资者在买卖公司股份时需保持谨慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192696072","title":"瑞博生物-B公布2026年9月股份变动月报 股本总数维持1.71亿元不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1192696072","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192696072?lang=zh_cn&edition=full","pubTime":"2026-10-07 18:42","pubTimestamp":1791369732,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年10月7日披露截至2026年9月30日的证券变动月报，更新公司9月期间股本及库存股份变化情况。报告显示，公司法定/注册股本为人民币1.71亿元，与上月底持平。公司已发行普通股H股总数为170,554,910股，亦与上月底相同。该等股份目前被列为库存股份，尚未注销，已发行股本总数因此并未发生变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671267715","title":"瑞博生物-B午前涨逾5% 公司自动化智能药物筛选中心落成","url":"https://stock-news.laohu8.com/highlight/detail?id=2671267715","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671267715?lang=zh_cn&edition=full","pubTime":"2026-09-29 11:30","pubTimestamp":1790652600,"startTime":"0","endTime":"0","summary":"模拟交易客户端瑞博生物-B午前涨逾5%，截至发稿，股价上涨4.88%，现报53.65港元，成交额358.05万港元。近日，据瑞博生物官微消息，公司宣布，旗下全资子公司瑞博泰克（山东）生物医药科技有限公司自动化智能药物筛选中心正式落成。瑞博生物正迎来管线成果加速释放阶段：自研肝靶向技术持续成熟，肝外递送技术获得重要突破。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnfqm3016755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBOT","BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671621822","title":"港股异动 | 瑞博生物-B(06938.HK)涨超5% 自动化智能药物筛选中心落成 公司迎管线成果加速释放阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2671621822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671621822?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:35","pubTimestamp":1790649323,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669093891","title":"港股全日表现疲软 恒指收跌1.01% OpenClaw概念股受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2669093891","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669093891?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:26","pubTimestamp":1790151963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股全日表现疲软，午后跌幅进一步扩大，三大股指均跌逾1%，截至收盘，恒生指数报24834.12点，下跌1.01%；国企指数下跌1.06%；恒生科技指数下跌1.33%。个股方面，老铺黄金盘中股价持续受压下挫，全天收跌2.70%。总结下半年，该行预计老铺黄金收入料介于75亿至105亿元人民币，同比下跌15%至39%，净利润介于12.6亿至20.1亿元人民币，净利润率16.8%至19.2%。招商证券国际发报告指，瑞博生物2026年上半年实现收入4.2亿元，超市场预期，截至中报在手现金22亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCHmain","06938","HHImain","HSI","HSTECH","SG9999001051.SGD","513600","03115","BK1161","SGXZ90724238.SGD","83115","03037","07300","02833","06181","BK1544","03419","82800","02800","07200","09115","07500","BK1227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669717746","title":"瑞博生物-B（06938）午后涨3.36% 机构指其纳入港股通 基本面和资金面多维度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2669717746","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669717746?lang=zh_cn&edition=full","pubTime":"2026-09-23 13:22","pubTimestamp":1790140964,"startTime":"0","endTime":"0","summary":"金吾财讯 | 瑞博生物-B（06938）股价反复扬升，午后升幅微扩，最新报56.85港元，涨3.36%，成交额468.35万港元。招商证券国际发报告指，瑞博生物2026年上半年实现收入4.2亿元，超市场预期，截至中报在手现金22亿元。RBD4059针对心房颤动和VTE的临床2b稳步推进，预计将进行4个2b期临床。另外，公司纳入港股通，基本面和资金面多维度提升。基于临床II期以上开发阶段的4款资产（3款拥有全球权益+1款国内权益授权给齐鲁），该行预计公司2026-2028年营业收入分别为4.4/1.2/1.5亿元人民币。维持瑞博生物目标价105港元以及“增持”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLHK","BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157825605","title":"瑞博生物-B2026年中期财报：营收4.20亿元，同比增长304.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157825605","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157825605?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:37","pubTimestamp":1789979854,"startTime":"0","endTime":"0","summary":"本季度信息\n瑞博生物-B（06938）发布的2026年中期财报显示，报告期内实现营收4.20亿元，同比增长304.3%。毛利4.01亿元，同比增幅达312.2%。经营活动所产生的现金流量净额从上年同期的-0.96亿元转为2.13亿元，呈现明显改善。\n报告期内公司加大了研发投入，研发费用约为1.98亿元，较上年同期的1.29亿元增长53.0%，研发投入占营收比约为47.14%。销售及分销开支同比下降14.5%，管理层指出主要由于营销推广费用减少所致；行政开支则同比增加20.9%，主要由与上市相关的专业及咨询服务费提升所带动。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"瑞博生物-B2026年中期财报：营收4.20亿元，同比增长304.3%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154234281","title":"瑞博生物-B：9月16日回购18.16万股，耗资约933.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154234281","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154234281?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:02","pubTimestamp":1789560161,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月16日发布翌日披露报表，披露当日于香港联交所场内回购H股股份。根据公告，本次回购数量为181,600股，占当日前已发行股本约0.107%，最高回购价为每股港币52元，最低回购价为每股港币49.96元，合计耗资约9,331,640港元。此前，公司于2026年6月5日获股东大会通过股份回购授权，总计可回购17,055,491股。公司表示，本次回购严格遵守香港联交所上市规则及有关法律法规。本公告由联席公司秘书张甦签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月16日回购18.16万股，耗资约933.16万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988108","title":"瑞博生物-B(06938.HK)9月16日斥资约933.16万港元回购18.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988108?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:00","pubTimestamp":1789560026,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186497229","title":"瑞博生物-B：9月11日回购171,800股，耗资约934.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186497229","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186497229?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:42","pubTimestamp":1789134177,"startTime":"0","endTime":"0","summary":"2026年9月11日，苏州瑞博生物技术股份有限公司发布公告，披露于同日于香港联交所场内回购股份171,800股，占该公司此前已发行股份总数的0.1011%。本次回购每股价格介乎53.20港元至55.70港元，合计耗资约9,347,770港元。公司回购授权于2026年6月5日获股东大会通过，授权回购股份总数为17,055,491股，截至目前已在香港联交所或其他证券交易所累计回购790,400股，占授权当日已发行股份总数的0.4634%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月11日回购171,800股，耗资约934.78万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552717","title":"瑞博生物-B(06938.HK)9月11日斥资934.8万港元回购17.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666552717?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:32","pubTimestamp":1789133540,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169606176","title":"瑞博生物-B：9月9日回购3.26万股，耗资约188.27万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169606176","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169606176?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:15","pubTimestamp":1788952552,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月9日发布翌日披露报表，公告显示公司于当日回购了32,600股H股普通股，占回购前已发行股份总数的约0.0192%。本次回购于香港联交所场内进行，回购价格为每股57.75港元，合计耗资1,882,650港元，折合约188.27万港元。公司回购授权于2026年6月5日获得股东大会批准，授权可回购股份总数为17,055,491股。公司在报告中强调，已遵守香港联合交易所证券上市规则与相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月9日回购3.26万股，耗资约188.27万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134573401","title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134573401","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134573401?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:45","pubTimestamp":1788867955,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年9月8日发布翌日披露报表。公司于当日通过香港联交所场内回购股份1.66万股，占回购前已发行股本的约0.0098%。本次回购每股价格为57.75港元，总耗资约95.87万港元。回购后，公司已发行股本由169,985,510股减少至169,968,910股，同时库藏股数增加至586,000股，总股本维持在170,554,910股。本次回购已获得公司董事会授权，并符合相关上市规则及法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：9月8日回购1.66万股，耗资约95.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665272123","title":"瑞博生物-B(06938)9月8日斥资95.87万港元回购1.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665272123","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665272123?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:44","pubTimestamp":1788867853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年9月8日斥资95.87万港元回购1.66万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":-0.0188},{"period":"3month","weight":-0.0315},{"period":"6month","weight":-0.1931},{"period":"1year","weight":-0.0987},{"period":"ytd","weight":-0.0987}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}